Overview: CYP2C19 Genotyping TestIntroduction: The CYP2C19 Genotyping Test analyzes CYP2C19 gene variants to assess drug metabolism, aiding personalized treatment for heart or psychiatric conditions. Following 2023 CPIC guidelines, it uses PCR for high specificity, aiding in pharmacogenetic screening. This test is critical for guiding medication selection, dosing, and improving outcomes in molecular pathology for patients requiring tailored therapy.
Other Names: CYP2C19 Pharmacogenetic Test, Drug Metabolism Genotyping.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: CYP2C19 genotyping began in the 2000s with pharmacogenetic research. Real-time PCR emerged in the 2010s, improving accuracy for drug metabolism profiling.
Purpose: Assesses CYP2C19 metabolism, guides medication selection, and optimizes treatment for patients with heart or psychiatric conditions.
Test Parameters: 1. CYP2C19 Genotype
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva at any time. Report current medications, especially clopidogrel or antidepressants.
Specimen: 2-5 mL whole blood (EDTA), 1-2 buccal swabs (sterile swab), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document heart or psychiatric conditions, and current medications (e.g., clopidogrel, SSRIs). Include family history of drug metabolism issues.
Consent: Written consent required, detailing the tests purpose, implications for drug therapy, and potential need for alternative medications.
Procedural Considerations: Uses PCR to detect CYP2C19 gene variants. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Contamination or improper storage can affect results. Low DNA yield may reduce sensitivity.
Clinical Significance: Variant genotypes (e.g., poor metabolizer) guide alternative drug selection or dosing. Normal genotypes support standard therapy.
Specialist Consultation: Consult a pharmacogeneticist or cardiologist/psychiatrist for result interpretation.
Additional Supporting Tests: CYP2D6 genotyping, drug level monitoring, or cardiac function tests to optimize therapy.
Test Limitations: Results may not account for all drug interactions. Clinical correlation is required.
References: CPIC Pharmacogenetic Guidelines, 2023; Clinical Pharmacology & Therapeutics, Scott SA, 2022.
